Cellebrite DI (CLBT) EBITDA (2020 - 2025)

Cellebrite DI's EBITDA history runs 6 years deep, the most recent figure standing at $20.8 million for Q4 2025.

• In Q4 2025, EBITDA rose 1145.81% year-over-year to $20.8 million; the TTM figure through Dec 2025 stood at $66.5 million (down 71.26% YoY), while the FY2025 annual figure was $66.5 million, down 33.1% from the prior year.
• EBITDA was $20.8 million for Q4 2025 at Cellebrite DI, up from $19.0 million in the prior quarter.
• In the past five years, EBITDA ranged from a high of $207.9 million in Q3 2024 to a low of -$3.1 million in Q3 2021.
• Historically, EBITDA has averaged $23.8 million across 5 years, with a median of $10.8 million in 2024.
• The sharpest annual moves came in 2021 and 2022: EBITDA plunged 134.42% in 2021, then soared 11114.98% in 2022.
• A 5-year view of EBITDA shows it stood at $1.4 million in 2021, then soared by 464.34% to $8.2 million in 2022, then plunged by 91.96% to $658000.0 in 2023, then soared by 153.8% to $1.7 million in 2024, then surged by 1145.81% to $20.8 million in 2025.
• The last three EBITDA figures came in at $20.8 million (Q4 2025), $19.0 million (Q3 2025), and $14.4 million (Q2 2025), per Business Quant data.